百濟神州(06160.HK)替雷利珠單抗獲美國批准治療食管鱗狀細胞癌

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

百濟神州(06160.HK)替雷利珠單抗獲美國批准治療食管鱗狀細胞癌

阿思達克 03-15 08:52

百濟神州(06160.HK)公布，美國食品藥監局(FDA)已批准替雷利珠單抗(百澤安，TEVIMBRA)作為單藥治療既往接受過系統化療(不含PD-1/L1抑制劑)後不可切除或轉移性食管鱗狀細胞癌(ESCC)的成人患者。替雷利珠單抗預計將於今年下半年在美國上市。

Relevant Stocks

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

百濟神州(06160.HK)替雷利珠單抗獲美國批准治療食管鱗狀細胞癌

Services

About Us

Agreement Statement